Very few treatments tested in preclinical studies make their way into clinical trials—of 5000 compounds tested in animals, approximately 5 will show enough promise in human trials for a company to file an Investigational New Drug Application with the US Food and Drug Administration.
Many preclinical studies fail to achieve their full potential in human trials for a number of reasons ranging from shortcomings in design to insufficient funding. The struggle to bring research from the bench to the bedside may indicate a need to update the traditional relationship between basic scientists and clinicians, according to a recent commentary in Cell. The authors argue that instead of a one-way track to patients, there should be a circular path from bench to bedside and back again.
Hampton T. Bench to Bedside and Back Again May Be Key to Clinical Breakthroughs. JAMA. 2017;318(1):16-17. doi:10.1001/jama.2017.7276